A number of leading pharmaceuticals executives have said that recent US tax reforms will create a more conducive environment for patent transactions. Corroborating forecasts made leading industry analysts suggest that 2018 will see a significant surge in this kind of deal-making in the life sciences sector.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is a high quality magazine with in-depth articles about intellectual asset management not found in any other publication. It adds value to our profession!

Katharine Ku
Director of the office of technology licensing
Stanford University

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?